Goldman Sachs’s Citius Pharmaceuticals CTXR Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-37,940
| Closed | -$19K | – | 5044 |
|
|
2024
Q3 | $19K | Sell |
37,940
-1,148,619
| -97% | -$575K | ﹤0.01% | 4708 |
|
|
2024
Q2 | $693K | Buy |
1,186,559
+1,099,074
| +1,256% | +$642K | ﹤0.01% | 3786 |
|
|
2024
Q1 | $78.5K | Sell |
87,485
-5,072
| -5% | -$4.55K | ﹤0.01% | 4493 |
|
|
2023
Q4 | $70K | Sell |
92,557
-61,734
| -40% | -$46.7K | ﹤0.01% | 4511 |
|
|
2023
Q3 | $106K | Sell |
154,291
-88,161
| -36% | -$60.3K | ﹤0.01% | 4379 |
|
|
2023
Q2 | $291K | Buy |
+242,452
| New | +$291K | ﹤0.01% | 4240 |
|
|
2023
Q1 | – | Sell |
-13,340
| Closed | -$10.5K | – | 5133 |
|
|
2022
Q4 | $10.5K | Buy |
+13,340
| New | +$10.5K | ﹤0.01% | 4939 |
|
|
2022
Q3 | – | Sell |
-221,256
| Closed | -$203K | – | 5504 |
|
|
2022
Q2 | $203K | Buy |
221,256
+72,222
| +48% | +$66.3K | ﹤0.01% | 4889 |
|
|
2022
Q1 | $267K | Buy |
149,034
+90,648
| +155% | +$162K | ﹤0.01% | 4940 |
|
|
2021
Q4 | $90K | Sell |
58,386
-138,735
| -70% | -$214K | ﹤0.01% | 5249 |
|
|
2021
Q3 | $401K | Buy |
197,121
+83,357
| +73% | +$170K | ﹤0.01% | 4506 |
|
|
2021
Q2 | $396K | Buy |
+113,764
| New | +$396K | ﹤0.01% | 4554 |
|
|
2017
Q4 | – | Sell |
-11,574
| Closed | -$36K | – | 4173 |
|
|
2017
Q3 | $36K | Buy |
+11,574
| New | +$36K | ﹤0.01% | 4152 |
|